Pain Therapeutics’ Remoxy Approval Hinges On REMS; FDA Unsure If Drug Is Abuse-Resistant
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees will discuss whether the proposed REMS can adequately determine abuse of the opioid.